InMed Pharmaceuticals Inc.
INM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001728328
In the last 90 days, InMed Pharmaceuticals Inc. insiders filed 4 open-market purchases and 0 sales; 20 institutions reported holding it in 13F filings for Q2 2026, worth $5.18M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $161.6K in total
- 4
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +11 vs. previous quarter
- 20
- 13F valueReported value at the end of Q2 2026
- $5.18M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding INM, Q2 2026
No superinvestor reported holding INM at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by InMed Pharmaceuticals Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 (view filing)6:58 PM ET | Sep 14-16 | 2 days | Schneeberger Daniel and 1 other10% Owner | PPurchase | +91.1K | $1.30 | +$118.1K | +11.4%892.1K after | 3 lots |
| Jul 17, 2026 (view filing)7:29 PM ET | Jul 15 | 2 days | Schneeberger Daniel and 1 other10% Owner | PPurchase | +1.00K | $1.56 | +$1.55K | +0.1%801.0K after | |
| Jul 16, 2026 (view filing)9:58 PM ET | Jul 14-16 | 2 days | Vivo Opportunity, LLC and 3 others10% Owner | PPurchase | +20.5K | $1.55 | +$31.8K | +37.7%75.0K after | 6 lots |
| Jul 2, 2026 (view filing)7:02 PM ET | Jun 30-Jul 2 | 2 days | Vivo Opportunity, LLC and 3 others10% Owner | PPurchase | +6.55K | $1.55 | +$10.1K | +9.8%73.1K after | 6 lots |
| Jun 10, 2026 (view filing)9:14 PM ET | May 20-Jun 8 | 21 daysLate | Vivo Opportunity, LLC and 3 others10% Owner | PPurchase | +249.2K | $1.57 | +$391.6K | New position72.5K after | 18 lots |
| May 21, 2026 (view filing)5:08 PM ET | May 19 | 2 days | Schneeberger Daniel and 1 other10% Owner | PPurchase | +468.6K | $1.54 | +$721.5K | +141.4%800.0K after | 3 lots |
| Aug 2, 2024 (view filing)4:02 PM ET | Jul 31 | 2 days | Mancini Alexandra Diane JanetOther: Consultant | SSale | −240 | $0.1763 | −$42.31 | −100.0%0 after | |
| Feb 22, 2024 (view filing)1:38 PM ET | Feb 21 | 1 day | Hull AndrewDirector | PPurchase | +37.5K | $0.39 | +$14.6K | +4,947.2%38.3K after | |
| Feb 21, 2024 (view filing)2:58 PM ET | Feb 20 | 1 day | Adams Eric APresident & CEO | PPurchase | +41.6K | $0.3587 | +$14.9K | +1,763.5%44.0K after | |
| Apr 18, 2022 (view filing) | Apr 14 | 4 days | Adams Eric APresident & CEO | PPurchase | +14.2K | $0.89 | +$12.6K | +31.6%59.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in InMed Pharmaceuticals Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 800,000 | $1.24M | 0.06% | +800,000 | New |
| Vivo Capital, LLC | 798,377 | $1.24M | 0.11% | +798,377 | New |
| Banque Cantonale Vaudoise | 6 | $1.00M | 0.00% | 00.0% | Unchanged |
| Squadron Capital Management LLC | 325,000 | $503.8K | 0.17% | +325,000 | New |
| Ikarian Capital, LLC | 245,025 | $379.8K | 0.06% | +245,025 | New |
| Ursa Fund Management, LLC | 125,800 | $195.0K | 0.03% | +125,800 | New |
| Suvretta Capital Management, LLC | 100,000 | $155.0K | 0.00% | +100,000 | New |
| Boothbay Fund Management, LLC | 74,244 | $115.1K | 0.00% | +74,244 | New |
| Sabby Management, LLC | 44,970 | $69.7K | 0.58% | −175,290−79.6% | Reduced |
| Jane Street Group, LLC | 43,078 | $66.8K | 0.00% | +43,078 | New |